Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass

Inclusion Criteria: * Signed informed consent; * Male or postmenopausal female; * Age ≥45 and ≤59 years old; * The body mass index (BMI) ≥18.5kg/m2 and ≤28 kg/m2; * T value of areal bone mineral density on any lumbar spine (L1-L4) or collum femoris\>-2.5 and \<-1; * The comprehensive physical examination is eligible or slightly abnormal but the researchers determine no clinical implication; * No smoking, alcohol or drugs abuse. Exclusion Criteria: * Any disease affecting bone metabolism; * Past medical history of cerebral infarction or cerebral arterial thrombosis; * Past medical history of myocardial infarction; * Administration of the following drugs within 6m: Hormone replacement therapy, Calcitonin Parathyroid hormone (or any derivative), Supplemental Vitamin D\>1,000 IU/day, Glucocorticosteroids (inhaled or topical corticosteroids administered more than 2 weeks before the enrollment date are allowed), Anabolic steroids, Calcitriol and available analogues, thiazide diuretics; * Administration of the following drugs within 12m: Bisphosphonates, Fluoride for osteoporosis; * A bone fracture within the previous 6 months; * A lumbar spine L1-L4 or femoral neck T-score ≤-2.5; * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT) or total bilirubin, more than 1.5 x ULN during screening; * 3 months prior to screening involved in any drug clinical subjects; * Subjects determined by the researchers have any food, dietary supplement or drugs that affect SHR-1222 absorption, distribution, metabolism and excretion in 4 weeks prior to screening or within 5 half-lives; * Serious infection, trauma or major surgery in 4 weeks prior to screening; * A surgery plan during the study; * Blood donation and transfusion in 3 months prior to screening; * Unstable thyroid dysfunction in 6 months prior to screening; * Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive; * Intolerant to venous blood collection; * A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar； * Subjects with any other situation should not be involved, which determined by the researchers.